Featured Previously Recorded Webinars

PD-L1 IHC 22C3 pharmDx and NSCLC One Assay, Two Platforms

Date: 08 Dec 2020
Presenter: Grant Toland, R&D Scientist, Agilent Technologies

The Nuances of Tumor Types: How are Cutoffs Determined and Validated?

Date: 05 Nov 2020

Implementation of PD-L1 Testing in the New Era of an Everchanging Immuno-oncology Landscape

Date: 24 Sep 2020

Mastering Combined Positive Score (CPS) From Principles to Real-world Applications

Date: 27 May 2020





More previously recorded webinars


The Pathologist and the Oncologist Working Together on PD-L1 to Improve Patient Treatment

Date: 11 Dec 2019

External Quality Assurance of PD-L1 Assays The NordiQCExperience

Date: 04 Dec 2019

The Rationale Behind the Scoring Systems for PD-L1 IHC to Determine Patients Eligible for KEYTRUDA (pembrolizumab)

Date: 24 Sep 2019

The Value of CDx IHC Assays in the Complex Environment of PD‑L1 Testing

Date: 28 May 2019

The Value of Participation in a PD-L1 EQA Program PD-L1 Implementation in EQA Programs

Date: 26 Oct 2017

Introduction to PD-L1 interpretation in gastric or gastroesphageal junction adenocarcinoma

Date: 17 Oct 2017

Advanced PD-L1 Interpretation

Date: 27 Sep 2017

Basic Interpretation of PD-L1 Expression

Date: 01 Jun 2017

How to Easily and Simply Implement PD-L1 Testing in Your Lab

Date: 20 Apr 2017

A Blueprint to PD-L1 Testing - Development and Value of the PD-L1 22C3 Assay

Date: 06 Apr 2017